Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical significance of genetic aberrations in secondary acute myeloid leukemia.
Milosevic JD, Puda A, Malcovati L, Berg T, Hofbauer M, Stukalov A, Klampfl T, Harutyunyan AS, Gisslinger H, Gisslinger B, Burjanivova T, Rumi E, Pietra D, Elena C, Vannucchi AM, Doubek M, Dvorakova D, Robesova B, Wieser R, Koller E, Suvajdzic N, Tomin D, Tosic N, Colinge J, Racil Z, Steurer M, Pavlovic S, Cazzola M, Kralovics R. Milosevic JD, et al. Among authors: elena c. Am J Hematol. 2012 Nov;87(11):1010-6. doi: 10.1002/ajh.23309. Epub 2012 Aug 7. Am J Hematol. 2012. PMID: 22887079 Free article.
Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients.
Cutica I, Riva S, Orlandi EM, Iurlo A, Vener C, Elena C, Bucelli C, Cattaneo D, Tomezzoli E, Pravettoni G. Cutica I, et al. Among authors: elena c. Patient Prefer Adherence. 2022 Oct 31;16:2963-2975. doi: 10.2147/PPA.S369326. eCollection 2022. Patient Prefer Adherence. 2022. PMID: 36338243 Free PMC article.
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.
Iurlo A, Cattaneo D, Consonni D, Castagnetti F, Miggiano MC, Binotto G, Bonifacio M, Rege-Cambrin G, Tiribelli M, Lunghi F, Gozzini A, Pregno P, Abruzzese E, Capodanno I, Bucelli C, Pizzuti M, Artuso S, Iezza M, Scalzulli E, La Barba G, Maggi A, Russo S, Elena C, Scortechini AR, Tafuri A, Latagliata R, Caocci G, Bocchia M, Galimberti S, Luciano L, Fava C, Foà R, Saglio G, Rosti G, Breccia M. Iurlo A, et al. Among authors: elena c. Front Pharmacol. 2023 Mar 23;14:1154377. doi: 10.3389/fphar.2023.1154377. eCollection 2023. Front Pharmacol. 2023. PMID: 37033642 Free PMC article.
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.
Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E, Del Curto C, Pietra D, Vanelli L, Bernasconi P, Pascutto C, Cazzola M, Morra E, Lazzarino M. Passamonti F, et al. Among authors: elena c. Blood. 2008 Apr 1;111(7):3383-7. doi: 10.1182/blood-2007-11-121434. Epub 2008 Jan 10. Blood. 2008. PMID: 18187660 Free article.
Blast phase of essential thrombocythemia: A single center study.
Passamonti F, Rumi E, Arcaini L, Elena C, Castagnola C, Zappasodi P, Bernasconi P, Pietra D, Pascutto C, Cazzola M, Lazzarino M. Passamonti F, et al. Among authors: elena c. Am J Hematol. 2009 Oct;84(10):641-4. doi: 10.1002/ajh.21496. Am J Hematol. 2009. PMID: 19691103 Free article.
Validation of cytogenetic-based risk stratification in primary myelofibrosis.
Rumi E, Passamonti F, Bernasconi P, Arcaini L, Pietra D, Elena C, Boveri E, Pascutto C, Cazzola M, Lazzarino M. Rumi E, et al. Among authors: elena c. Blood. 2010 Apr 1;115(13):2719-20. doi: 10.1182/blood-2009-12-258988. Blood. 2010. PMID: 20360476 Free article. No abstract available.
Mutational status of myeloproliferative neoplasms.
Rumi E, Elena C, Passamonti F. Rumi E, et al. Among authors: elena c. Crit Rev Eukaryot Gene Expr. 2010;20(1):61-76. doi: 10.1615/critreveukargeneexpr.v20.i1.50. Crit Rev Eukaryot Gene Expr. 2010. PMID: 20528738 Review.
155 results